Zoetis (ZTS) stock is in focus after the European Commission granted marketing authorization for Poulvac Procerta HVT-ND, a single-dose poultry vaccine that provides dual protection against Newcastle disease and Marek's disease.

Even with the Poulvac Procerta HVT-ND approval in Europe and recent shifts in its Russell index membership, Zoetis is still dealing with weak momentum, with the share price down 40.36% year to date and the 1-year total shareholder return down 51.81%.

If this kind of sector specific news has your attention, it could be a good moment to see what other animal health and veterinary related plays are doing across 40 healthcare AI stocks

Zoetis still has a sizeable, globally diversified animal health business, yet the stock has fallen sharply and now sits well below many published targets. Is that gap pointing to value, or signalling deeper concerns about what you are paying for?

Most Popular Narrative: 19.2% Undervalued

Zoetis closed at $75.10, while the most followed narrative on the stock, using a fair value of $92.92, frames the recent sell off as an opportunity gap rather than a value trap.

The main reason for the recent collapse in the share price was because they reported that the US Companion Animal segment saw a 11% YoY decline in segment revenues. As that’s where they’re supposed to be focusing on most, given the higher margins and higher defensibility/moat of profits of the Pet segment, it is no surprise that it resulted in a 30% drop in the share price after Q1 earnings.

Want to understand why a business with single digit revenue and earnings growth still screens as undervalued here? According to ValueInvestingSubstack, the narrative focuses on sustained margins, disciplined pricing and a valuation multiple that assumes steady, not spectacular, expansion. The gap between that view and today’s share price is where the full story sits.

Result: Fair Value of $92.92 (UNDERVALUED)

However, the Zoetis narrative still faces pressure from the 11% revenue decline in US companion animals and the use of additional debt to fund buybacks.

Next Steps

Mixed on Zoetis after reading this far? Take a moment to weigh both sides for yourself by reviewing the 5 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Zoetis?

If Zoetis has you rethinking your watchlist, now is the moment to widen the lens and look for other opportunities before the market prices them in.

• Spot promising smaller companies early by scanning 20 elite penny stocks with strong financials that already show stronger financial foundations than many expect from this corner of the market.
• Look for quality stocks that may be trading below what their fundamentals suggest by reviewing the 44 high quality undervalued stocks while prices still appear appealing.
• Focus on stability and capital preservation first by checking the 72 resilient stocks with low risk scores if you want potential upside without taking on the highest volatility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.